利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.045 秒)

    Human C3b/C4b receptor (CR1)
    1.
    发明授权
    Human C3b/C4b receptor (CR1) 失效
    人C3b / C4b受体（CR1）

    公开(公告)号：US06316604B1

    公开(公告)日：2001-11-13

    申请号：US08463959

    申请日：1995-06-05

    申请人： Douglas T. Fearon ,  Lloyd B. Klickstein ,  Winnie W. Wong ,  Gerald R. Carson ,  Michael F. Concino ,  Stephen H. Ip ,  Savvas C. Makrides ,  Henry C. Marsh, Jr.

    发明人： Douglas T. Fearon ,  Lloyd B. Klickstein ,  Winnie W. Wong ,  Gerald R. Carson ,  Michael F. Concino ,  Stephen H. Ip ,  Savvas C. Makrides ,  Henry C. Marsh, Jr.

    IPC分类号： C07K14435

    CPC分类号： C07K14/70596 ,  A61K38/00 ,  Y02A50/473

    摘要： The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

    摘要翻译： 本发明涉及C3b / C4b受体（CR1）基因及其编码蛋白。 本发明还涉及包含70个核苷酸的CR1核酸序列及其片段及其编码的肽或包含24个氨基酸的蛋白质。 本发明进一步提供CR1蛋白及其片段的表达。 本发明的基因和蛋白质在诊断和治疗涉及补体活性的疾病以及各种免疫系统或炎性疾病中具有应用。 在下文实施例部分详述的本发明的具体实施方案中，描述了全长CR1 cDNA及其片段的克隆，核苷酸序列和推导的氨基酸序列。 还描述了CR1蛋白及其片段的表达。 还描述了缺乏跨膜区的分泌型CR1分子的表达。 分泌的CR1分子显示可用于减少由炎症引起的损伤和降低心肌梗死面积并防止再灌注损伤。

    Human C3b/C4b receptor (CR1)
    4.
    发明授权
    Human C3b/C4b receptor (CR1) 失效
    人C3b / C4b受体（CR1）

    公开(公告)号：US5981481A

    公开(公告)日：1999-11-09

    申请号：US470652

    申请日：1995-06-06

    申请人： Douglas T. Fearon ,  Lloyd B. Klickstein ,  Winnie W. Wong ,  Gerald R. Carson ,  Michael F. Concino ,  Stephen H. Ip ,  Savvas C. Makrides ,  Henry C. Marsh, Jr.

    发明人： Douglas T. Fearon ,  Lloyd B. Klickstein ,  Winnie W. Wong ,  Gerald R. Carson ,  Michael F. Concino ,  Stephen H. Ip ,  Savvas C. Makrides ,  Henry C. Marsh, Jr.

    IPC分类号： A61K38/00 ,  C07K14/705 ,  A61K38/18 ,  C07K14/46 ,  C12P21/00

    CPC分类号： C07K14/70596 ,  A61K38/00

    摘要： The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

    摘要翻译： 本发明涉及C3b / C4b受体（CR1）基因及其编码蛋白。 本发明进一步提供CR1蛋白及其片段的表达。 本发明的基因和蛋白质在诊断和治疗涉及补体活性的疾病以及各种免疫系统或炎性疾病中具有应用。 在下文实施例部分详述的本发明的具体实施方案中，描述了全长CR1 cDNA及其片段的克隆，核苷酸序列和推导的氨基酸序列。 还描述了CR1蛋白及其片段的表达。 还描述了缺乏跨膜区的分泌型CR1分子的表达。 分泌的CR1分子显示可用于减少由炎症引起的损伤和降低心肌梗死面积并防止再灌注损伤。

    Nucleic acids encoding a human C3b/C4b receptor (CR1)
    6.
    发明授权
    Nucleic acids encoding a human C3b/C4b receptor (CR1) 失效
    编码人C3b / C4b受体（CR1）的核酸

    公开(公告)号：US5212071A

    公开(公告)日：1993-05-18

    申请号：US332865

    申请日：1989-04-03

    申请人： Douglas T. Fearon ,  Lloyd B. Klickstein ,  Winnie W. Wong ,  Gerald R. Carson ,  Michael F. Concino ,  Stephen H. Ip ,  Savvas C. Makrides

    发明人： Douglas T. Fearon ,  Lloyd B. Klickstein ,  Winnie W. Wong ,  Gerald R. Carson ,  Michael F. Concino ,  Stephen H. Ip ,  Savvas C. Makrides

    IPC分类号： A61K38/00 ,  C07K14/705 ,  C12N15/12

    CPC分类号： C07K14/70596 ,  A61K38/00

    摘要： The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

    摘要翻译： 本发明涉及C3b / C4b受体（CR1）基因及其编码蛋白。 本发明还涉及包含70个核苷酸的CR1核酸序列及其片段及其编码的肽或包含24个氨基酸的蛋白质。 本发明进一步提供CR1蛋白及其片段的表达。 本发明的基因和蛋白质在诊断和治疗涉及补体活性的疾病以及各种免疫系统或炎性疾病中具有应用。 在下文实施例部分详述的本发明的具体实施方案中，描述了全长CR1 cDNA及其片段的克隆，核苷酸序列和推导的氨基酸序列。 还描述了CR1蛋白及其片段的表达。 还描述了缺乏跨膜区的分泌型CR1分子的表达。 分泌的CR1分子显示可用于减少由炎症引起的损伤和降低心肌梗死面积并防止再灌注损伤。

    Modulating the immune response
    7.
    发明授权
    Modulating the immune response 失效
    调节免疫反应

    公开(公告)号：US06891027B2

    公开(公告)日：2005-05-10

    申请号：US09850715

    申请日：2001-05-07

    申请人： Douglas T. Fearon ,  Paul W. Dempsey

    发明人： Douglas T. Fearon ,  Paul W. Dempsey

    IPC分类号： A61K47/48 ,  A61P37/00 ,  A61P37/02 ,  C12P21/04 ,  C07H21/02 ,  C12N15/62

    CPC分类号： A61K47/6849 ,  A61K47/646

    摘要： Coupling of C3d molecules or ligands of CD21 or CD19 to an antigen alters the level of immune response to the immunogen upon its administration to an individual. For C3d, the magnitude of the effect is dependent on the number of C3d molecules included in the conjugate. Conveniently, C3d molecules or CD21/CD19 ligands are coupled to an immunogen in fusion polypeptides which may be produced by expression from coding nucleic acid, for instance by culturing host cells containing the nucleic acid. Other means of associating the molecules include chemical cross-linking and co-expression on the surface of a carrier structure. Administration of compositions comprising, in a preferred embodiment, C3d molecules and an immunogen of interest may be used prophylactically (by virtue of the immunological memory induced) or therapeutically. The administration may be for the purpose of raising antibodies to the immunogen. A T-cell response may also be induced.

    摘要翻译： C3d分子或CD21或CD19的配体与抗原的偶联可以在给予个体时改变对免疫原的免疫应答水平。 对于C3d，效应的大小取决于包含在缀合物中的C3d分子的数目。 方便地，C3d分子或CD21 / CD19配体与可通过编码核酸的表达产生的融合多肽中的免疫原偶联，例如通过培养含有核酸的宿主细胞。 关联分子的其它方法包括在载体结构的表面上的化学交联和共表达。 在优选实施方案中，包含C3d分子和感兴趣的免疫原的组合物的施用可以预防性地使用（通过诱导免疫记忆）或治疗性地使用。 给药可能是为了增加针对免疫原的抗体。 也可诱导T细胞反应。

    Soluble complement regulatory molecules
    8.
    发明授权
    Soluble complement regulatory molecules 失效
    可溶补体调节分子

    公开(公告)号：US06458360B1

    公开(公告)日：2002-10-01

    申请号：US07949472

    申请日：1992-12-28

    申请人： Douglas T. Fearon ,  Thomas Hebell

    发明人： Douglas T. Fearon ,  Thomas Hebell

    IPC分类号： A61K39395

    CPC分类号： C07K14/705 ,  A61K38/00 ,  C07K16/18 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/32

    摘要： This invention is directed to a soluble recombinant fused protein which is stable in the mammalian circulatory system comprising a polypeptide which contains a recognition site for a target molecule, such as a complement receptor site, and is joined to the N-terminal end of an immunoglobulin chain. The invention is also directed to a construct comprising a plurality of peptides containing short consensus repeats having a complement binding site attached to a soluble, physiologically compatible, macromolecular carrier. The invention is particularly useful for inhibiting complement activation or complement-dependent cellular activation in mammals.

    摘要翻译： 本发明涉及在哺乳动物循环系统中稳定的可溶性重组融合蛋白，其包含含有靶分子如补体受体位点的识别位点的多肽，并且连接到免疫球蛋白的N末端 链。 本发明还涉及包含多个含有短共有重复序列的构建体的构建物，其具有连接到可溶性，生理上相容的大分子载体的补体结合位点。 本发明特别可用于抑制哺乳动物中的补体活化或补体依赖性细胞活化。

    Compositions and methods employing a ligand for CD21 or CD19 for modulating the immune response to an antigen
    9.
    发明授权
    Compositions and methods employing a ligand for CD21 or CD19 for modulating the immune response to an antigen 失效
    使用CD21或CD19配体调节抗原免疫应答的组合物和方法

    公开(公告)号：US06238670B1

    公开(公告)日：2001-05-29

    申请号：US08849488

    申请日：1997-10-21

    申请人： Douglas T. Fearon ,  Paul W. Dempsey

    发明人： Douglas T. Fearon ,  Paul W. Dempsey

    IPC分类号： A61K3900

    CPC分类号： A61K47/6849 ,  A61K47/646

    摘要： Described herein are compositions which modulate the immune response. In one aspect, a composition is described which comprises an antigen covalently linked to a ligand for CD21(CR2) or CD19. This antigen is not associated with a complement C3 fragment through an ester bond derived from the internal thioester of the complement C3 fragment.

    摘要翻译： 本文描述了调节免疫应答的组合物。 一方面，描述了包含与CD21（CR2）或CD19的配体共价连接的抗原的组合物。 该抗原通过衍生自补体C3片段的内部硫代酯的酯键与补体C3片段不相关。